MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
468.97%
Quick Ratio
427.65%
Cash Ratio
217.18%
Debt to Asset Ratio
148.98%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Accounts receivable, net
    • Inventories
    • Others
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in capital
    • Long-term debt
    • Others
Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash and cash equivalents
109,968
110,745
90,039
92,904
Marketable securities
30,306
9,711
36,994
64,050
Restricted cash
1,327
1,350
1,347
1,082
Accounts receivable, net
55,412
33,082
19,703
19,649
Inventories
20,921
16,464
8,341
7,128
Prepaid expenses and other current assets
19,530
14,672
12,122
12,055
Total current assets
237,464
186,024
168,546
196,868
Property and equipment, net
616
637
695
688
Marketable securities
-
0
380
4,632
Restricted deposit
177
177
177
177
Right-of-use assets, operating and finance leases
7,940
8,456
8,489
5,551
Other non-current assets
7,493
5,161
6,759
801
Total assets
253,690
200,455
185,046
208,717
Accounts payable and accrued expenses
35,346
27,717
26,173
30,962
Employee related accrued expenses
9,837
13,516
11,114
11,646
Other liabilities, current
5,452
5,185
4,957
4,940
Total current liabilities
50,635
46,418
42,244
47,548
Prepaid forward obligation
128,228
127,276
126,067
124,833
Long-term debt
189,530
122,210
122,111
122,508
Lease, liabilities, noncurrent
5,647
6,122
6,241
3,413
Uncertain tax positions liability
3,903
3,903
3,791
3,791
Total liabilities
377,943
305,929
300,454
302,093
Ordinary shares, nis 0.01 par value, 100,000,000 shares authorized at march 31, 2026 and december 31, 2025 48,708,280 and 48,350,272 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively
134
133
128
126
Additional paid-in capital
858,895
854,090
817,793
806,497
Retained Earnings Accumulated Deficit
-
-
-
-900,005
Accumulated deficit
-983,290
-959,716
-933,352
-900,000
Accumulated other comprehensive income
8
19
23
6
Total shareholders' deficit
-124,253
-105,474
-115,408
-93,376
Total liabilities and shareholders' deficit
253,690
200,455
185,046
208,717
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$109,968K Accounts receivable, net$55,412K Marketable securities$30,306K Inventories$20,921K Prepaid expenses andother current assets$19,530K Restricted cash$1,327K Total current assets$237,464K Right-of-use assets,operating and finance...$7,940K Other non-currentassets$7,493K Property and equipment,net$616K Restricted deposit$177K Total assets$253,690K Accumulated deficit-$983,290K Total liabilities andshareholders' deficit$253,690K Total shareholders'deficit-$124,253K Additional paid-in capital$858,895K Ordinary shares, nis 0.01par value,...$134K Accumulated othercomprehensive income$8K Total liabilities$377,943K Long-term debt$189,530K Prepaid forwardobligation$128,228K Total currentliabilities$50,635K Lease, liabilities,noncurrent$5,647K Uncertain tax positionsliability$3,903K Accounts payable andaccrued expenses$35,346K Employee related accruedexpenses$9,837K Other liabilities,current$5,452K

UroGen Pharma Ltd. (URGN)

UroGen Pharma Ltd. (URGN)